Reiterating timelines for FDA submission in 2025Transplant clinical trial has attracted leading transplant hospitalsBooked first revenue from first-generation GraftAssureIQ research-use-only kits; began shipping second generation kits in June NASHVILLE, Tenn., Aug. 11, 2025 (GLOBE NEWSWIRE) -- Insight Molecular Diagnostics Inc., or iMDx, (Nasdaq: IMDX), today published the following letter to shareholders in conjunction with its second quarter results: Fellow shareholders, We are closer than we have ever be ...